Ibutamoren (LUM-201) Phase 3 Trial in Children Recruiting

A Phase 3 clinical trial involving LUM-201, a compound related to ibutamoren, was listed as recruiting as of August 3, 2026. The study, titled "Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency," is registered under identifier NCT06948214. According to the listing, the trial is currently in Phase 3 and has a status of recruiting. The study focuses on children with growth hormone deficiency, though no results or outcome data have been reported at this stage. This update reflects only the trial's registration status and does not indicate any findings regarding safety or effectiveness. Recruitment status can change as studies progress, and further updates may be posted to the same registry entry over time. Readers interested in tracking this trial can consult the official ClinicalTrials.gov listing for the most current information. As with any clinical study update, this brief reports only what has been disclosed in the registration record. No conclusions about therapeutic benefit or risk can be drawn from a recruiting status alone. For more background on ibutamoren generally, readers can consult the compound overview for additional context.